COVID-19 Vaccination: Selected U.S. Data Sources

COVID-19 Vaccination: Selected U.S. Data Sources

link to page 2

INSIGHTi

COVID-19 Vaccination: Selected U.S. Data
Sources
Updated October 21, 2022
The sources below can help congressional staff track the U.S. Coronavirus Disease 2019 (COVID-19)
vaccination campaign.
This list reflects selected sources of frequently requested data. Methodologies differ between sources;
readers can check websites’ notes and caveats for more information on how their data were collected and
other important methodological concerns. For help interpreting data, congressional staff can contact CRS.
In addition to the list of vaccination data sources, information on public attitudes toward vaccination
includes CDC’s National Immunization Survey, COVIDVaxView, and State of Vaccine Confidence
Insights Report, Kaiser Family Foundation, and a number of scholarly articles.
Vaccines.gov maps vaccination sites. Vaccine Equity Planner (Ariadne Labs) helps identify areas that lack
convenient vaccine access.
About Vaccine Data
State and local jurisdictions, federal agencies, and pharmacy partners determine the number and types of
doses shipped (distributed) to vaccination sites. Providers then administer doses to patients and report
administration data to jurisdictions and CDC. (See CDC’s COVID-19 Vaccination Data in the United
States.)
FDA has approved or authorized for emergency use several COVID-19 vaccines, summarized in Table 1.
Congressional Research Service
https://crsreports.congress.gov
IN11595
CRS INSIGHT
Prepared for Members and
Committees of Congress

Congressional Research Service
2
Table 1. COVID-19 Vaccines Approved or Authorized by FDA
(as of October 19, 2022)
Pfizer-BioNTech
Moderna
J&J/Janssen
Novavax
Primary Series
Monovalent vaccine:
Monovalent vaccine:
One dose (ages 18+) Two doses (ages 12+)
• three doses (ages 6 months
• two doses (ages 6 months+)
through 4 years)
• three doses (certain
• three doses (certain
immunocompromised individuals
immunocompromised individuals
aged 6 months+)
aged 5+)
• two doses (ages 5+)
FDA Approval/Licensure
Yes, monovalent vaccine
Yes, monovalent vaccine
Not approved
Not approved
approved under the name
approved under the name
Comirnaty as a two-dose regimen Spikevax as a two-dose regimen
for individuals 12+
for individuals 18+
Emergency Use Authorization (EUA)
Yes, monovalent vaccine
Yes, monovalent vaccine
Yes, authorized in
Yes, authorized as a
authorized as a
authorized as a
limited situations due • two-dose primary series
• three-dose primary series for
• two-dose primary series for
to risk of serious
for ages 12+
ages 6 months through 4 years
ages 6 months+
adverse events:
• single booster dose for
• two-dose primary series for
• third primary series dose for
• single-dose primary ages 18+
ages 5+
certain immunocompromised
series for ages 18+
• third dose for certain
individuals aged 6 months+
• single booster dose
immunocompromised individuals

for ages 18+
aged 5+
Yes, bivalent vaccine authorized

as a single booster for ages 6+
Yes, bivalent vaccine authorized
as a single booster for ages 5+
Source: CRS based on FDA’s COVID-19 Vaccines.
Notes: See FDA’s COVID-19 Vaccines for details. Monovalent vaccines contain a messenger RNA (mRNA) component from
the original strain of SARS-CoV-2, the virus that causes COVID-19. Bivalent vaccines contain two mRNA components of
SARS-CoV-2, one from the original strain and one from the Omicron BA.4/BA.5 variants. The J&J/Janssen and Novavax
vaccines are only available as monovalent vaccines.
CDC and FDA maintain websites on recommended regimens and booster eligibility.
Vaccination Data Sources
CDC provides data on doses and people vaccinated, and aggregated data for certain federal entities
(Bureau of Prisons, Department of Defense, Indian Health Service, and Veterans Health Administration;
see “Data Table”). CDC also publishes vaccine effectiveness data.
CDC (click map) compiles links to state dashboards, which may also track sub-state data.
Non-CDC sources that provide analyses of CDC data and incorporate data from jurisdiction-specific
sources include the following:
 Covid Act Now (CAN)
 Health Equity Tracker (HET)

link to page 3 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 link to page 4 Congressional Research Service
3
 Kaiser Family Foundation (KFF)
 Centers for Medicare & Medicaid Services (CMS)
Table 2 links to websites containing vaccination statistics.
Table 2. Links to Vaccination Data Sources
Measure
National
State
Local
Doses distributed
Number
CDC
CDC
—
Per capita
CDC (download Data CDC
—
Table)
By vaccine type (J&J/Janssen,
CDC
CDC (download Data
—
Spikevax/Moderna,
Table)
Comirnaty/Pfizer-BioNTech,
Novavax, and updated (bivalent)
boosters)
Doses administered
Number
CDC
CDC

Per capita
CDC (download Data CDC
—
Table)
Per day (daily count and 7-day
CDCa
CDCa
—
average, trend)
By vaccine type
CDC
CDC (download Data
—
Table)
Booster doses administered in last 7
CDCb
CDCb
—
days
People vaccinated
People who received ≥1 dose
CDC (also trend)a
CDC (also trend)a
CDC (county)
(number)
CDC (CBSA)b
People who received ≥1 dose
CDC
CDC
CDC (county)
(percentage)
CAN
CANc
CDC (CBSA)b
CAN (county, metro
area)c
People fully vaccinatedd (number)
CDC (also trend)a
CDC (also trend)a
CDC (county)

CDC (CBSA)b
People fully vaccinatedd (percentage)
CDC
CDC
CDC (county, also case

CANc
rates and testing positivity
map)

CDC (CBSA)b
CAN (county, metro
area)c
People with booster doses
CDC (also trend)
CDC (download Data
CDC (county)
Table) (also trend)
CDC (CBSA)b
CANc
CAN (county, metro
area)c

link to page 4 link to page 4 Congressional Research Service
4
Measure
National
State
Local
Demographics
CDC (race/ethnicity,
CDC (sex, age, trends; also
CDC (age, county and
sex, age; also trends)
maps)
CBSA)b
CDC (aged 65+)
CDC (aged 65+)
CDC (aged 65+, county)
CDC (trends by age,
CDCb (age)
CDC (social vulnerability,
alongside cases)
CDC (urban/rural, trend)
urban/rural, county)
CDCb (people
CDCb (people initiating
CDC (people initiating
initiating vaccination
vaccination or receiving
vaccination or receiving
or receiving booster
booster in last 7 days, by
booster in last 7 days, by
in last 7 days, by age)
age)
age, county and CBSA)b
CDC (disability status HET (race/ethnicity)

and age,
race/ethnicity)
KFF (race/ethnicity)
CDC (pregnant
people by
race/ethnicity, trend)
CDC (urban/rural,
trend)
HET (race/ethnicity)
KFF (race/ethnicity)
Nursing homes
Resident/staff vaccination rates
CDC (trend)
CDC (trend)
CMS (facility-level data in
CMS
CMS
“Search for a nursing
home”)
Medicare.gov (facility-level
data)
Source: CRS based on sources as of October 6, 2022.
a. See also 7-day average trend alongside cases or deaths, see “View (right axis).”
b. See spreadsheets under “Show More”: “Attachments.” Metropolitan and Micropolitan Statistical Areas are collectively
known as Core-Based Statistical Areas (CBSAs).
c. Search state, city, or county, then scroll to “% Vaccinated” for trend.
d. “Fully vaccinated” people have received the second dose of a two-dose vaccine or one dose of a single-shot vaccine
(CDC).
e. Includes number, percentage, vaccine type.

Author Information

Ada S. Cornell
Angela Napili
Senior Research Librarian
Senior Research Librarian

Disclaimer

Congressional Research Service
5
This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff
to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of
Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of
information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role.
CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United
States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However,
as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the
permission of the copyright holder if you wish to copy or otherwise use copyrighted material.

IN11595 · VERSION 23 · UPDATED